NeuroOne Medical Tech Bolsa (NASDAQ: NMTC)

Últimas noticias sobre NeuroOne Medical Tech (NASDAQ:NMTC) Bolsa

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AMS, GES, NMTC, SLP y SGMO.

5 acciones en el foco este viernes: AMS, GES, NMTC, SLP y SGMO

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

Piper Sandler analyst Patrick Moley maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and lowers the price target from $220 to $213.

Price Target

Analyst Ratings

MKTX

Piper Sandler Maintains Neutral on MarketAxess Holdings, Lowers Price Target to $213

Macro Economic Events

Politics

Global

Economics

General

White House Economic Adviser Hassett Says Getting Ready To Present A Plan To Trump On Who And When For Tariff Talks; Trump Wants Fair And Reciprocal Trade, Will Weigh That As He Decides Whether To Accept Countries' Offers; Focused Like Laser Beam On Big Trading Partners That Have Been Giving Us Trade Deficits For Years; Fed Will Decide Interest Rates, Respect Independence; On China, Says We Are Prioritizing Trading Partners For Talks; We Are Prioritizing Our Allies And Trading Partners

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $15 price target.

CRMD

D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing the recent PARASOL recommendations expected to shorten drug development time and approval for rare kidney disease, FSGS. The full text of the letter follows.
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER
ZyVersa is developing Cholesterol Efflux Mediator&#x2122;&nbsp;VAR 200 for treatment of chronic kidney diseases, initially focusing on FSGS as the lead. Plans for indication expansion include treatments for Alport Syndrome and Diabetic Kidney Disease. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research).
Today, I am thrilled to update you on a recent advancement that is expected to be a giant step forward in FSGS drug development and anticipated to derisk development of VAR 200 for its lead indication, FSGS. Prior to conducting Phase 2 clinical trials in FSGS, we are initiating a small Phase 2a proof-of-concept trial with VAR 200 in the first half of this year in patients with DKD. The intent of the study is to quickly obtain first in human renal data prior to initiating a larger phase 2a/b trial in patients with FSGS. The DKD data will also provide insights to help optimize protocol design for the subsequent FSGS study.
FSGS is a devastating, progressive, and complex rare kidney disorder affecting around 40,000 people in the US. It is a leading cause of kidney failure, requiring dialysis and transplant for survival. With FSGS, it is common for patients to need more than one kidney transplant since the disease can affect the new kidney in a relatively short period of time. FSGS has an overwhelming negative impact on daily living and quality of life. Disease symptoms, such as fatigue and chronic severe swelling, and the number of required drugs and their side effects interfere with daily activities. It is common for patients to miss a large percentage of school or work days making it challenging to graduate or hold a job. Likewise, patients, especially children, are often hospitalized missing holidays and family celebrations, including their own birthdays. Additionally, patients with FSGS experience a substantial degree of anxiety and emotional impact from fear of needing dialysis or transplant, and from concern about exposure to infectious diseases resulting from the immunosuppressive drugs they are on. This leads to social isolation and loneliness. Kidney failure not only affects patients' quality of life but has a high economic burden. In 2023, an estimated $28 billion was spent on dialysis care and $3.4 billion on transplant patient care. To date, there are no approved drug therapies that effectively prevent or delay FSGS progression to kidney failure.
One reason for the lack of drug treatments is the high regulatory hurdle requiring drug developers to demonstrate a substantially reduced FSGS progression to kidney failure. FSGS trials can require decades of follow-up in large study populations to measure kidney failure. This is generally not feasible in clinical trials, especially for rare kidney diseases.
Thanks to the initiative of a multi-stakeholder group of rare kidney disease experts and the FDA to identify a robust surrogate endpoint to replace long-term kidney failure outcomes (the PARASOL initiative), it is expected that shorter clinical trials with fewer patients will be required to demonstrate FSGS drug efficacy. The Parasol group recommended a reduction in proteinuria (spillage of protein into the urine) over 24 months as a surrogate endpoint for full regulatory approval of FSGS drugs. According to Dr. Aliza Thompson, PARASOL's Co-chair and Director of the Cardio-Renal Division at the FDA, "Data supporting the recommendation came from over 25 studies conducted all over the globe and involved more than 1,600 patients, providing a robust foundation for informed regulatory decisions."
Travere is likely to be the first company to benefit from the PARASOL group's recommendations. Despite a 50% reduction in proteinuria, FDA previously denied accelerated approval for Filspari (sparsentan) for FSGS because the drug failed to demonstrate a reduced progression to kidney failure (based on surrogate marker eGFR). The recent PARASOL recommendations are expected to pave the way for FSGS approval for Filspari. Following a promising Type C meeting with the FDA in February, Travere filed a supplemental New Drug Application (sNDA) on March 17, 2025, seeking priority review for traditional approval of FILSPARI&#xAE; for treatment of FSGS. FDA approval is anticipated in the third quarter of this year, with launch by year's end.
In an April 3, 2025 analyst update on Travere, Guggenheim indicated that they believe investors underappreciate the FSGS commercial opportunity, which is substantially larger than that for IgAN. This is based on a higher unmet need for effective FSGS drug therapies since patients progress to kidney failure at twice the rate as IgAN patients, and there are fewer expected competitors reducing price sensitivity. Guggenheim has projected $2 Billion in peak sales for Filspari in FSGS.
We are excited about the potential approval of Filspari for FSGS based on a reduction in proteinuria, as it will further support proteinuria as the primary endpoint for VAR 200's FSGS clinical trials. Because VAR 200 targets a unique pathway leading to development and progression of FSGS and other kidney diseases (accumulation of cholesterol and lipids in the kidney's filtration system), VAR 200 will be used as add on therapy to Filspari and other standard of care drugs such as steroids and calcineurin inhibitors. For more information about Cholesterol Efflux Mediator&#x2122;&nbsp;VAR 200, <a href="https://www.globenewswire.com/Tracker?data=GJr9icsGx4FkAaK_4leQ2xXfjEFCwlD7Uvqo5F4k04RNhU3l9EZLKKmqD0k9wPBVjJnis7ZpJ8yU4_Mxb5FmOglDYqa1SDHhoPFP-pEAzXJYIe8mtRB6v_9Vowi_L5xBG9tVVPn8yr3Xy9gGbhvxktn5REFw5XhRJ8ZVYl6FiNjTVnnrfdwmm8_e2-GDGwhW">Click Here</a>.
We thank you for your continued support.
Sincerely, Stephen C. Glover Co-Founder, Chairman, Chief Executive Officer, and President ZyVersa Therapeutics

Biotech

ZVSA

ZyVersa Therapeutics CEO Highlights Recent PARASOL Recommendations To Accelerate Drug Development For FSGS, Announces Phase 2a Proof-Of-Concept Trial For VAR 200 In Diabetic Kidney Disease, And Discusses Potential Impact On Kidney Disease Treatment And Commercial Opportunities

WIIM

SOPH

SOPHiA GENETICS shares are trading higher after the company announced a strategic partnership with Precision For Medicine to enhance patient stratification and targeted therapy development.

Piper Sandler analyst Patrick Moley maintains Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Overweight and lowers the price target from $210 to $192.

IBKR

Piper Sandler Maintains Overweight on Interactive Brokers Group, Lowers Price Target to $192

Shares of EV battery swapping technology provider U Power Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Tuesday.
The company advanced its clean energy ambitions in Southeast Asia with a <a href="https://www.benzinga.com/pressreleases/25/04/n44681132/u-power-limited-nasdaq-ucar-conducts-southeast-asias-first-public-demonstration-of-battery-swap-st">successful demonstration of its UOTTA battery</a> swap station at the 2025 Bangkok International Motor Show.
The company presented its battery swapping technology in collaboration with partners such as Susco Public Company Limited (SUSCO).
The showcased battery-swapping station is set to enter commercial service in Phuket as part of an agreement with Susco.
This deployment represents Southeast Asia's first operational battery exchange system. By tapping into Susco's extensive fueling station network across Thailand's busiest travel and transport corridors, the initiative is strategically positioned for swift expansion in areas with high tourism and logistics demand.
Also Read: <a href="https://www.benzinga.com/25/04/44671636/nvidia-applied-materials-provide-115m-fund-to-digital-engineering-startup-rescale">Nvidia, Applied Materials Back Digital Engineering Startup In $115M Round</a>
&#8220;This public demonstration marks more than a technical milestone — it&#8217;s a blueprint for scalable electrification across ASEAN&#8217;s tourism economies,&#8221; stated&nbsp;CEO Johnny Lee.
&#8220;As Thailand&#8217;s pioneer operational battery swap provider, we&#8217;re delivering infrastructure that grows in lockstep with market demand, supported by cross-sector partnerships and aligned with national policy frameworks.&#8221;&nbsp;
This achievement also initiates a larger infrastructure expansion outlined in the partnership deal reached in March 2025.
With joint investments and aligned execution strategies, U Power intends to create uniform rollout procedures customized for Thailand's tourism-driven coastal regions, supporting the country's goals for electric vehicle integration.
Following its installation in Phuket, the station will first serve electric taxis and ride-hailing providers based on pre-established business agreements. 
UOTTA's open-framework design lets regional energy collaborators adopt the system with limited initial costs, fostering a cooperative and expandable development model.
The initiative aligns with Thailand's EV 3.5 policy, which extends incentives for consumers who adopt battery-swappable electric vehicles through 2027. 
Price Action: UCAR shares traded higher by 10.9% at $2.94 in premarket at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44671105/cloudflare-acquires-outerbase-to-streamline-ai-app-development-our-goal-is-to-make-it-easy-and-accessible-for-any-developer">Cloudflare Acquires Outerbase To Streamline AI App Development, &#8216;Our Goal Is To Make It Easy And Accessible For Any Developer&#8217;</a>
Photo: Shutterstock

UCAR

U Power Launches Southeast Asia's First Battery Swap Station, Stock Surges

SLNH

Soluna Holdings shares are trading higher after the company announced it has signed a term sheet for a 120 MW data center project.

AMTX

Aemetics shares are trading higher after the company announced a 55% production increase of renewable natural gas for March.

<a href="https://www.globenewswire.com/Tracker?data=7G-0nNgbDdAExGKOqxZ5SLi7OrRY8Dx290h7f2D6msguThfsjkrFZCewrEINkQneLbETaRYgA7xeENXBWj58aYdPlwX9h4bq9uD6icC3PW8H7KULqdmrJGxgGwq6fGujM_zkICXqlicsRsX-RurZqg==">&nbsp;American Battery Technology Company</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>), an integrated critical battery materials company that is commercializing its technologies for both primary battery minerals manufacturing and secondary minerals lithium-ion battery recycling, has completed its fourth drill program at its <a href="https://www.globenewswire.com/Tracker?data=l86Zz1HxZvBFkdatLmIUeZgGbp7ql5jdO10mgqKk1XL5PavNR_7T1vn3y8bbqMSpZQ7GRIlJyVReFjbXM6QiWtljHD8fkWX0282dPVvPXT3HeLZrBirQDjPev146h-MCv8rf-9cMnlT7uaKiyijsJbl8tj17P0MoR7yzuw2lyKY=">Tonopah Flats Lithium Project</a> (TFLP). This marks an important milestone in the company's effort to accelerate the commercialization of its domestic lithium resource in alignment with President Trump's recent executive order <a href="https://www.globenewswire.com/Tracker?data=gY5KThL3Ym2G2HB3DYWBHIw0jBxs_YBTozBiK5qzfzaygwYQNK5AF0by8B2Dkyh0KxtL5VVbzPduu7KgMiT_oc9h7d-jC8bdoAaFdUTMZmwGD2kZsxK9objfEXjwGJr3m1viED1wj8wNiTH3QPKb18C_n__Av_JaqGyXizu9jDmlu0TCeIrL0A5nK8UIxIcF9mVUL5FZ_igzc3b_LFGM2EvyWOSc26FdMIB9RRTYHTs9ISYscD7Ngg4Ul9LeHLjMRT7Q5008hHFn1hrqx3cgHw==">Immediate Measures to Increase American Mineral Production</a>.

ABAT

American Battery Technology Company Completes Fourth Drill Program At Tonopah Flats Lithium Project, Advancing Efforts To Commercialize Domestic Lithium Resources

CLSD

Clearside Biomedical shares are trading higher. Needham reiterated a Buy rating on the stock.

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and maintains $50 price target.

Reiteration

HRMY

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

OTLK

Outlook Therapeutics shares are trading higher after the company announced FDA acknowledgment for its receipt of resubmission of the Biologics License Application for ONS-5010.

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is taking heat week after week from one of its most outspoken investors. Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, came out swinging after the company reported weak sales in first quarter for some of its high-end electric vehicles.
<h2 class="wp-block-heading">Sales Dip Adds Fuel to the Fire</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">These numbers suck. Tesla other models (Cybertruck, S and X) sold only 12,881 versus last year 17,027. This is down 25%. The high end EV business has totally eroded. The cybertruck is basically not selling. The brand is broken and may not be fixable. The BOD is 100% responsible…
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1907428713358373363?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;These numbers suck,&#8221; Gerber wrote on X,&nbsp; referring to Tesla's Cybertruck, Model S and Model X, which he says sold just 12,881 units—down 25% from the 17,027 sold in the same period last year. &#8220;The high-end EV business has totally eroded. The Cybertruck is basically not selling. The brand is broken and may not be fixable.&#8221;
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
<h2 class="wp-block-heading">Calls for Leadership Change</h2>
Gerber pinned the blame squarely on Tesla's board: &#8220;The BOD is 100% responsible and should be removed for negligence,&#8221; he said.
His frustration isn't new, but it appears to be intensifying. In a recent CNN <a href="https://www.youtube.com/watch?v=rqXuiBGlGsU">interview</a>, Gerber said, &#8220;There isn't more that Elon could do to turn off customers from Tesla. I really don't think there's more he could do to turn off customers from Tesla. I really don't think there's more he could do.&#8221;
He also criticized Musk&#8217;s growing political presence, including his involvement in President Donald Trump's administration. Gerber suggested that Musk is more focused on his government role than on running Tesla.
&#8220;If he's going to work in the government, I'm all for it,&#8221; Gerber said. &#8220;But then why isn't somebody else running Tesla?&#8221;
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
<h2 class="wp-block-heading">Marketing Crisis and Brand Damage</h2>
Gerber said Tesla's biggest issue now isn't just about operations. &#8220;It's the image and marketing problem that the company now has, which in my mind is in a crisis at this point.&#8221;
He pointed to incidents like <a href="https://www.benzinga.com/news/25/03/44463376/tesla-showroom-targeted-in-austin-as-vandalism-escalates">vandalism and protests at Tesla showrooms</a> as signs of a brand in serious trouble. &#8220;Literally terrorist attacks on Tesla showrooms. People burning the most environmentally friendly vehicle ever made.&#8221;
Even the much-hyped Cybertruck, once marketed as bulletproof and indestructible, <a href="https://www.benzinga.com/markets/equities/25/03/44414187/elon-musks-tesla-recalls-over-46000-cybertrucks-due-to-safety-concerns">has seen eight recalls</a>, including one over panels that can peel off while driving.
<h2 class="wp-block-heading">Criticism of Robyn Denholm</h2>
Gerber also blasted Tesla Chair Robyn Denholm, accusing her of failing to act in the interest of shareholders. &#8220;Robyn Denholm is the woman paid off to do NOTHING to protect the 83% of Tesla investors she is negligently representing. She only represents one shareholder, Musk,&#8221; he <a href="https://x.com/GerberKawasaki/status/1901771876793504092">posted</a> on X last month.
See Also: <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a>
Since joining Tesla's board in 2014, Denholm has <a href="https://www.benzinga.com/news/25/03/44436256/tesla-may-be-tanking-but-robyn-denholm-is-winning-musks-hand-picked-tesla-chair-has-made-an-incredible-682-million-since-2014">earned an estimated $682 million</a> in cash and stock, according to a Reuters <a href="https://www.reuters.com/investigations/tesla-tanks-musks-hand-picked-board-chair-is-doing-just-fine-2025-03-17/">analysis</a>. She has already sold about $532 million worth of Tesla shares, some as recently as early March, right before Tesla's stock plunged.
A Delaware judge recently criticized her for approving Musk&#8217;s record-setting $56 billion pay package, writing that &#8220;outsized director compensation can compromise independence.&#8221;
<h2 class="wp-block-heading">Can Tesla Bounce Back?</h2>
Tesla reported its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year">first-ever annual sales decline</a> in 2024, and its stock has dropped more than 29% year-to-date, at the time of writing. While Musk has promised to double U.S. vehicle production over the next two years, many investors remain skeptical.
&#8220;I warned about this a year ago,&#8221; Gerber said. &#8220;Tesla needed to work to separate itself from Elon&#8230; now it might be too late.&#8221;
For now, the pressure is mounting. As Tesla&#8217;s challenges grow, so do questions about whether its leadership and brand can recover.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

TSLA

Tesla Sales Numbers 'Suck,' Says Ross Gerber. He Claims The Tesla Brand Is Broken Because Of The Board That Should Be Removed For Negligence

NAOV

NanoVibronix Shares Resumed Trade

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares are trading higher Tuesday after the company authorized a <a href="https://www.benzinga.com/pressreleases/25/04/n44674029/broadcom-inc-announces-10-billion-share-repurchase-authorization">$10 billion share repurchase program</a>.
What Happened: Broadcom&#8217;s board authorized a new buyback program, allowing the company to repurchase up to $10 billion of its common stock by Dec. 31, 2025.
Broadcom said the repurchase authorization reflects the board's confidence in the company's diversified businesses and strong cash flow generation.
"Today's announcement of a&nbsp;$10 billion&nbsp;share repurchase program reflects the Board's confidence in the strength of Broadcom's diversified semiconductor and infrastructure software product franchises," said&nbsp;Hock Tan, president and CEO of Broadcom.
"In particular, we are uniquely positioned in mission critical infrastructure software and enabling hyperscalers to drive innovation in generative AI into their expanding subscriber platforms."
Check This Out: <a href="https://www.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Marvell Plays AI Hardball: Divestiture Sparks 155% Upside, Says Analyst</a>
Broadcom noted that it may repurchase shares in the open market or make privately negotiated purchases under the new buyback program, but the company is not obligated to repurchase any shares.
AVGO Price Action: <a href="http://benzinga.com/quote/avgo" target="_blank" rel="noreferrer noopener">Broadcom shares</a> were up 8.38% at $166.77 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Ken Wolter/Shutterstock.

Buybacks

Movers

AVGO

Broadcom Shares Are Trading Higher Tuesday: What's Going On?

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) with a Buy and maintains $31 price target.

CLNN

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target

NYXH

Nyxoah shares are trading higher after the company announced it's nearing FDA approval for Genio System. Additionally, HC Wainwright & Co. reiterated a Buy rating on the stock.

Needham analyst Ryan MacDonald reiterates DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) with a Buy and maintains $4 price target.

DCGO

Needham Reiterates Buy on DocGo, Maintains $4 Price Target

ASNS

Actelis Networks shares are trading higher after the company announced it received a new order to modernize Orange County's traffic infrastructure.

Press Releases

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Health Care

NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

Daxor

electroCore

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Femasys

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

NAYA Biosciences

Neuraxis

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Nexalin Technology

PAVmed

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Beyond Air

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Alliance Global Partners

Screenshot 2024-05-03 at 5.56.54 PM

Interview

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

Comments

NeuroOne Medical Tech

Noticias

Últimas noticias sobre NeuroOne Medical Tech (NASDAQ:NMTC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL